SCHEMBL5466271

SCHEMBL5466271

CCC1CC(N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)C(=O)OC)c2cc(C(F)(F)F)ccc2N1C(=O)OCCO

nearest known ligand 0.88

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CETP P11597 20/20 0.88

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14597747 1.00 CETP (0.88) CETP
SCHEMBL992972 1.00 CETP (0.88) CETP
SCHEMBL3411380 0.94 CETP (0.89) CETP
SCHEMBL992392 0.94 CETP (0.89) CETP
Torcetrapib SCHEMBL7169875 0.93 CETP (1.00) CETP
Torcetrapib SCHEMBL10041443 0.93 CETP (1.00) CETP
Torcetrapib SCHEMBL29403162 0.93 CETP (1.00) CETP
Torcetrapib SCHEMBL126708 0.93 CETP (1.00) CETP
Torcetrapib SCHEMBL49081 0.93 CETP (1.00) CETP
Torcetrapib SCHEMBL6277910 0.93 CETP (1.00) CETP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070004774-A1 Cept inhibitors and metabolites thereof PFIZER INC. 2007-01-04 US claimed
EP-1670765-A2 CETP INHIBITORS AND METABOLITES THEREOF Pfizer Products Inc. (US) 2006-06-21 EP claimed
WO-2005033082-A2 CETP INHIBITORS AND METABOLITES THEREOF PFIZER PRODUCTS INC. (US) 2005-04-14 WO claimed
US-20070004774-A1 Cept inhibitors and metabolites thereof PFIZER INC. 2007-01-04 US disclosed
EP-1670765-A2 CETP INHIBITORS AND METABOLITES THEREOF Pfizer Products Inc. (US) 2006-06-21 EP disclosed
EP-1607389-A1 4-protected-amino-2-substituted-1,2,3,4-tetrahydroquinolines as intermediates for CETP inhibitors Pfizer Products Inc. (US) 2005-12-21 EP disclosed
US-20050245570-A1 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines DENINNO MICHAEL P 2005-11-03 US disclosed
EP-1114031-B1 4-CARBOXYAMINO-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS PFIZER PROD INC (US) 2005-06-15 EP disclosed
US-6906082-B2 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines PFIZER INC. (US) 2005-06-14 US disclosed
WO-2005033082-A2 CETP INHIBITORS AND METABOLITES THEREOF PFIZER PRODUCTS INC. (US) 2005-04-14 WO disclosed
US-20040092550-A1 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines PFIZER INC. 2004-05-13 US disclosed
US-6586448-B1 Cholesteryl ester transfer protein inhibitors used as antilipemic agents for prophylaxis of cardiovascular disorders PFIZER INC. 2003-07-01 US disclosed
US-6197786-B1 ANTICHOLESTEROL AGENTS PFIZER INC 2001-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092550-A1 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines CETP, APOB, NR1H2 CETP 1/4885
US-20050245570-A1 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines CETP, APOB, HDLBP CETP 1/4885
US-20070004774-A1 Cept inhibitors and metabolites thereof CETP, LCAT, MTTP CETP 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.